Quanterix Corp. is a pioneering pharmaceutical company based in the United States of America. With an ESG risk rating score of 20.2, the company is considered to have a medium risk level. Quanterix Corp. specializes in developing cutting-edge ultra-sensitive digital immunoassay platforms that revolutionize precision health for life sciences research and diagnostics. Their innovative Simoa bead-based and planar array technologies allow for the reliable detection of protein biomarkers in low concentrations in bodily fluids, providing a level of accuracy that conventional methods cannot achieve. The company offers a range of products including Simoa, Assay Kits, LDTs & Assay Services, and cutting-edge instruments like the HD-X Automated Immunoassay Analyzer and the SR-X Biomarker Detection System. Quanterix Corp. is leading the way in advancing the ESG landscape in the pharmaceutical industry.